title: Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
abstract: Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNbeta-1a (Avonex) in relapsing- remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing--remitting MS.
authors.affiliation: Department of Biomedical Engineering, The Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: E
authors.initials: E
authors.lastname: Fisher
authors.forename: R A
authors.initials: RA
authors.lastname: Rudick
authors.forename: G
authors.initials: G
authors.lastname: Cutter
authors.forename: M
authors.initials: M
authors.lastname: Baier
authors.forename: D
authors.initials: D
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Weinstock-Guttman
authors.forename: M K
authors.initials: MK
authors.lastname: Mass
authors.forename: D S
authors.initials: DS
authors.lastname: Dougherty
authors.forename: N A
authors.initials: NA
authors.lastname: Simonian
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001284:Atrophy; D001921:Brain / Q000473:pathology* / Q000503:physiopathology*; D017326:Clinical Trials, Phase III as Topic; D004185:Disability Evaluation; D017352:Echo-Planar Imaging; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a